Eisai's Lemborexant (Dayvigo), China's First Dual Orexin Receptor Antagonist for Insomnia, Officially Launched

Jiemian News learned from Eisai China that on August 16, Eisai's innovative drug Lemborexant (brand name: Dayvigo) was officially launched in China. This product is the first dual orexin receptor antagonist approved in China, used to treat adult insomnia patients characterized by difficulty falling asleep and/or maintaining sleep. Meanwhile, Eisai China has reached a strategic cooperation with JD Health. Lemborexant has been exclusively launched on JD Health’s B2C and O2O channels. (Jiemian News reporter Chen Yang)